$MGRX Phallic Growth Among Small Cap StocksSmall cap stocks have been extremely hot lately and one of them is Mangoceuticals, Inc. (NASDAQ: MGRX) which has been gaining momentum due to a litany of sponsorship deals and its upcoming product launch. These moves reflect MGRX’s thorough understanding of marketing strategy because they precisely target its target audience while utilizing a growing underrated medium. Taking into account the significance of these sponsorships, MGRX’s revenues may increase drastically which might make MGRX stock one of the small cap stocks to watch especially since it is about to launch a sildenafil based product.
MGRX Fundamentals
Doubling Down On Podcasts
MGRX doubled down on its utilization of podcasts for marketing as it recently signed a partnership agreement with GaS Digital Network to promote MGRX’s products on multiple comedy podcasts. This move fits the company’s intricate yet playful persona by targeting its audience while introducing its product through the medium of comedy, which also thrives on discussing taboo subjects.
The terms of the agreement include that GaS Digital Network will generate 1 million unique impressions over the span of 2 months, which is significant since it has approximately 5 million listeners per month.
Viagra-ish
According to MGRX, its new Sildenafil based Mango flavored ED treatment will be available for purchase this summer. This product in and of itself could be considered a marketing ploy due to the fact that sildenafil is the active ingredient in Viagra. MGRX started trending online due to memes and social media commentary insinuating that its Cialis oriented treatment was a knockoff of Cialis.
That said, these digital transactions provide increased visibility and engagement. By utilizing Sildenafil, MGRX may be banking on duplicating this phenomenon in order to get additional engagements online. In this way, MGRX could see higher demand for its products – increasing its revenues.
Technical Analysis
MGRX stock is in a neutral trend and is trading in a sideways channel between $1.51, and $1.71. Looking at the indicators MGRX is trading above the 200, 50, and 21 MAs. Meanwhile, the RSI is neutral at 61 and the MACD is bullish.
As for the fundamentals, MGRX appears to be one of the small cap stocks poised to soar thanks to its groundbreaking sponsorships and its Sildenafil oriented ED product. With the company pursuing additional sponsorship deals, MGRX could soar if a new deal is announced.
MGRX Forecast
As things stand, MGRX may be the most prolific ED marketer to date as every move it makes seems optimized to increase its visibility. With a new product expected to be released this summer, MGRX could be on track to grow its revenues significantly this year. Given the company’s potential to secure additional sponsorship deals, MGRX stock is shaping to be one of the most interesting small cap stocks to watch this summer.
MGRX trade ideas
$MGRX Phallic Growth Among Small Cap StocksSmall cap stocks have been extremely hot lately and one of them is Mangoceuticals, Inc. (NASDAQ: MGRX) which has been gaining momentum since announcing its sponsorship of BarStool Sports’ sex podcast – Only Stans. This move reflects MGRX’s thorough understanding of marketing strategy because it precisely targets its target audience while utilizing a growing underrated medium. Taking into account the significance of this sponsorship, MGRX’s revenues may increase drastically which might make MGRX stock one of the small cap stocks to watch closely this year as it is pursuing additional sponsorship deals.
MGRX Fundamentals
The first few years of any company are critical since during that time corporations set strategic visions that could help it in achieving profitability or lead to its demise. MGRX was founded in 2021 which makes it a newcomer to the erectile dysfunction (ED) market. That said, its Only Stans sponsorship reflects an understanding of the sexually active demographic that other ED companies simply lack which is why the stock’s potential could be considered extremely promising.
The Checkered Past of ED Sponsorships
ED companies have a complicated history when it comes to sponsorships. In 2007, Viagria pulled out of its sponsorship deal with the MLB abruptly after it spent hundreds of millions of dollars. The reason is not specified however one could infer that the results of the sponsorship did not satisfy Viagra because the sponsorship did not target a specific audience. Another issue that ED sponsorship may face is a lack of comfort in advertising ED medications. A year before Viagra withdrew its sponsorship, a cluster of NFL teams withdrew their sponsorships with Levitra as the league did not feel comfortable being associated with an ED medication.
The differences between MGRX’s sponsorship deal and the aforementioned deals are simple – placement, and targeting. The Viagra and Levitra deals appeal to a large audience but they felt out of place. On the other hand, sex podcasting is a profession built on discussing a taboo subject matter which means that an ED sponsorship fits like a glove. Furthermore, sex podcast regulars are more likely to be sexually active which is desirable for an ED company.
The Desirability Of Sex Podcasts
The sexually active demographic could be seen as a simple manifestation of lust perpetuated by primal carnal desires, however, a closer look reveals a litany of overarching ideologies. Sex podcasts like Esther Perel’s Where Should We Begin, Doing It! with Hannah Witton, Only Stans, and many others discuss topics such as being autistic in the sex industry, paraphilias (atypical kinks), and raw sexual narratives that reveal the messiness of sex in its authentic form.
This medium is optimal for discussing ED because it emphasizes a central philosophy that focuses on demystifying sex and discussing it as if it were any other topic. This aforementioned philosophy is also the reason why Only Stans has an average of 320 thousand viewers, and why the sponsorship deal was a wise choice for MGRX.
Future Plans
As things stand MGRX did not give any details about the nature of any future marketing deals it might be considering, however, the company stated that it is “aggressively hunting additional sponsorship deals with similar media opportunities ”. That statement was made in regard to deals within BarStool Sports as well as similar organizations. That said, MGRX’s approach towards targeted marketing will help it acquire suitable sponsorships which will improve its chances of acquiring revenue from these deals. It is for that reason that its dedication to marketing-oriented growth is a clear market advantage that may catapult MGRX stock to new heights.
Short Data
As is, MGRX is one of those small cap stocks with short squeeze potential as its short data hint at a potential short squeeze. Currently, MGRX has a high cost to borrow of 410% and a 100% utilization rate, however, its short interest is only 6.2% and its float on loan is only 11%. Despite this, MGRX’s short data are increasing rapidly compared to last week which may see a short squeeze occur – especially since MGRX has a low float of 6.2 million.
MGRX Financials
According to MGRX’s Q1 report its assets increased fourfold QoQ from $1 million to $4.1 million which is mostly due to its cash balance increasing from $694 thousand to $3.7 million. Liabilities, on the other hand, decreased from $389 thousand to $296 thousand. This is extremely promising since it means that MGRX has more than enough cash on hand to cover its liabilities 10 times over which is incredibly impressive for small cap stocks – especially for a new company like MGRX.
Technical Analysis
MGRX stock is in a neutral trend with the stock trading in a sideways channel between its support at $1.60 and its resistance at $2.39. Looking at the indicators, the stock is above the 200, 50, and 21 MAs which are bullish indications. Meanwhile, the RSI is neutral at 55 and the MACD recently turned bullish.
As for its fundamentals, MGRX appears to be one of the small cap stocks poised to soar thanks to its groundbreaking sponsorship with Only Stans which might assist in garnering popularity and boosting sales. With the company pursuing additional sponsorship deals, MGRX could soar if a new deal is announced.
MGRX Forecast
ED sponsorships have a bad record due to a litany of reasons regarding accurately targeting a specific audience to hesitancy due to the nature of ED medications. GRMX’s sponsorship with Only Stans circumvents these issues because sex podcasts target sexually active adults and their profession is built on discussing taboo subjects. Due to these reasons, GRMX may see a notable increase in its revenues which is likely to be reflected in the stock performance.
MGRX - Opportunity for Erection Deep Discount IPO price NASDAQ:MGRX - Quiet Period Look for a Re-test of IPO 4 price
Somethings are Better Hard
www.youtube.com
Huge market potential
NASDAQ:MGRX 1.17 Under 13 Mil Market Cap
NYSE:HIMS 2.37 Bil Market Cap
MGRX recent IPO give investors a hard on as it executes its BP
Great marketing and potential in this stage of company lifecycle
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval;
They are basically selling a generic version of an approved medication and bypassing
the patent protections and betting they will fly under the regulator radar apparatus.
As might be expeted this recent nano-IPO is highlly volatile. Play with it only
if you have the requisite skills to do so and only with risk capital.
it does the marketing through direct to consumer telehealth services.
>>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
On review and analysis on the 30 minute chart, the price action is squeezing
down in a flat bottom triangle likely setting up a breakout upside.
The RSI oscillator shows RSI crossing 50% from below.
Volatility is compressing down inside the triangle for a squeeze set up.
Targets are based on the supply and demand zones of the Luxalgo indicator.
The first parget is the midline between the zones while the final target
is just below the supply zone. As can be seen on the chart, the first target
is about 100% upside while the final target is 200% upside. One of the
position is closed at each target making the return 150% overall.
Stop loss is below the demand zone. A stop loss is 15% yields an overall
reward to risk ration of 10:1.
MGRX Biotech Penny Stock Pullback for Continuation LONGMGRX with some FDA news catalyst got a lot of action on the last session of the week.
With the pullback and overwhelming volume during the session, a continuation into
the upcoming week is entirely reasonable. ( see also the link)
MGRX had a last price of about $1.50 about a 50% retracement from the high of the day.
I will take a position at market price in the pre-market opening the week. The
target will be $2.25 or midway between the current price and the high of the last session.
This will represent a 50% Return on Trading Position. I will set a stop loss at $ 1.40
representing a 10% loss. Price at present is sitting on a confluence of support of
both the 20 and 50 HMAs along with the lowermost VWAP band. The reward for risk is 5X.
MGRX does not have options. I expect the long trade to hit the continuation target
in less than 5 days. I will set a buy-stop order to take a position when the price exceeds
$ 1.55 with a stop loss of $0.15 to account for the expected volatility.
